ArticleExperimental and therapeutic medicine2018
Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Long-term disease control with anti-VEGF treat-and-extend treatment in macular edema due to retinal vein occlusion.BMC ophthalmology · 2026Article
- Evaluation of Anatomical and Tomographic Biomarkers as Predictive Visual Acuity Factors in Eyes with Retinal Vein Occlusion Treated with Dexamethasone Implant.Journal of clinical medicine · 2024Article
- Characteristics of macular edema associated with retinal vein occlusion showing poor anatomic response to three loading anti-vascular endothelial growth factor injections: an optical coherence tomography analysis.BMC ophthalmology · 2024Article
- CHAJournal of ophthalmology · 2024Article
- Potential Prognostic Indicators for Patients With Retinal Vein Occlusion.Frontiers in medicine · 2022Review
- Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept.BMC ophthalmology · 2021Article
- The impact of structural optical coherence tomography changes on visual function in retinal vein occlusion.Acta ophthalmologica · 2021Article
- Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab.BMC ophthalmology · 2021Observational
- Ocular microcirculation changes, measured with laser speckle flowgraphy and optical coherence tomography angiography, in branch retinal vein occlusion with macular edema treated by ranibizumab.International ophthalmology · 2021Article
- Article
- Optical coherence tomographic comparison of naive macular edema due to ischemic and nonischemic retinal vein occlusion.International ophthalmology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study investigated predictive factors for best-corrected visual acuity (BCVA) after ranibizumab treatment in patients with macular edema (ME) associated with retinal vein occlusion (RVO) with an original ranking for the impairment of macular microstructure. In this retrospective study, 31 eyes of 31 patients with RVO received 3 monthly consecutive ranibizumab injections and another 3 months of follow-up. An original method was applied to rank the impairment of the external limiting membrane (ELM) and the ellipsoid zone (previously called the photoreceptor inner and outer segment junction, IS/OS) integrity on the baseline optical coherence tomography (OCT) images. Univariate and multivariate linear regression analyses were performed to assess the association between the baseline factors and post-treatment BCVA. ELM integrity and baseline BCVA were shown to be independent factors in the prediction of post-treatment BCVA. Comparison of post-treatment BCVA between original ELM ranks after adjusting for the baseline BCVA revealed the ELM integrity beneath the center of the fovea was important to post-treatment BCVA. ELM integrity in particular beneath the center of the fovea and baseline BCVA may be more useful than other factors in the prediction of visual function in patients with ME secondary to RVO after ranibizumab injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.